4.1 Review

Novel Concept of a Heart-Gut Axis in the Pathophysiology of Heart Failure

期刊

KOREAN CIRCULATION JOURNAL
卷 47, 期 5, 页码 663-669

出版社

KOREAN SOC CARDIOLOGY
DOI: 10.4070/kcj.2017.0028

关键词

Gut epithelial barrier; Gastrointestinal microbiome; Dysbiosis; Microbe-derived metabolites

资金

  1. Japan Society for the Promotion of Science [KAKENHI 26670395]
  2. Takeda Pharmaceutical Co., Ltd.
  3. Daiichi Sankyo Co., Ltd.
  4. Shionogi Co., Ltd.
  5. Nippon Boehringer Ingelheim Co., Ltd.
  6. Bristol-Myers Squibb K.K.
  7. MSD K.K.
  8. Sanofi K.K.
  9. Mitsubishi Tanabe Pharma Corporation
  10. Sumitomo Dainippon Pharma Co., Ltd.

向作者/读者索取更多资源

Patients with heart failure (HF) have structural and functional changes of the gut as a result of microcirculatory disturbances. A disrupted gut epithelial barrier may lead to translocation of microbial products into systemic circulation, possibly aggravating HF by inducing inflammatory responses. Gut microbiota play an essential role in the maintenance of host homeostasis because large quantities of their gene products complement host physiological processes. Emerging evidence has suggested the potential clinical significance of gut microbiota in the pathophysiology of HF. Imbalances of gut microbe-derived metabolites can contribute to cardiac dysfunction and other morbidities in patients with HF. Therapeutic research for HF through targeting microbiota is under way. Thus, the novel concept of a heart-gut axis may lead to breakthroughs in the development of innovative diagnostics and therapeutic approaches for HF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据